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APS is an autoimmune disease in which antiphospholipid antibodies (aPL) cause vascular
thrombosis and pregnancy morbidity. In patients with APS, aPL exert pathogenic actions
by binding serum beta-2-glycoprotein I (β2GPI) via its N-terminal domain I (DI). We
previously showed that bacterially-expressed recombinant DI inhibits biological actions
of IgG derived from serum of patients with APS (APS-IgG). DI is too small (7 kDa)
to be a viable therapeutic agent. Addition of polyethylene glycol (PEGylation) to small
molecules enhances the serum half-life, reduces proteolytic targeting and can decrease
immunogenicity. It is a common method of tailoring pharmacokinetic parameters and
has been used in the production of many therapies in the clinic. However, PEGylation
of molecules may reduce their biological activity, and the size of the PEG group can
alter the balance between activity and half-life extension. Here we achieve production
of site-specific PEGylation of recombinant DI (PEG-DI) and describe the activities in vitro
and in vivo of three variants with different size PEG groups. All variants were able to inhibit
APS-IgG from: binding to whole β2GPI in ELISA, altering the clotting properties of human
plasma and promoting thrombosis and tissue factor expression in mice. These findings
provide an important step on the path to developing DI into a first-in-class therapeutic in
APS.
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INTRODUCTION
Antiphospholipid syndrome (APS) is an autoimmune disease in which antiphospholipid antibodies
(aPL) interact with phospholipid/protein complexes in the body to cause vascular thrombosis
and/or pregnancy morbidity (1). The exact population prevalence of APS is unknown but it
has been estimated that aPL may contribute to 6.1% of cases of pregnancy morbidity, 13.5% of
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strokes, 11.5% of myocardial infarctions, and 9.5% of deep vein
thromboses (DVT) (2). The only evidence-based treatment to
prevent recurrent thrombosis in patients with APS is long-
term anti-coagulation, generally with warfarin (3) though more
recently new oral anticoagulants such as rivaroxaban have been
used (4). Utility of these new oral anticoagulants however, is
not yet fully established in treatment of thrombotic APS. In
APS pregnancies, the standard of care remains daily treatment
with oral aspirin plus subcutaneous heparin (5). Unfortunately
recent data from the TRAPS trial has been disappointing with
thrombosis rates in patients on Rivaroxaban being significantly
higher (19 vs. 3%) (6). There is currently no therapeutic agent
that targets the biologic actions of aPL specifically.
The key autoantigen targeted by pathogenic aPL is beta-
2-glycoprotein I (β2GPI) (7), which consists of five domains
[Domain I to Domain V (DI to DV)]. The N-terminal DI
carries the key epitope recognized by aPL (8, 9). It is believed
that the aPL-β2GPI complex interacts with the surface of target
cells by means of binding between DV and negatively charged
phospholipids on the cell membrane (10). This interaction leads
to activation of cell surface receptors and intracellular signaling
cascades causing changes in cellular behavior that promote
thrombosis and/or pregnancy morbidity (10). Activation of
target endothelial cells (ECs), monocytes and platelets by aPL
induces the upregulation of several proinflammatory cytokines,
key among them being tissue factor (TF) (11, 12). In our
mouse thrombosis model utilizing knockout mice, we have
previously shown that aPL-mediated increases in inflammatory
cytokines, particularly TF levels, correlate with increased
thrombus formation in vivo (13).
Our hypothesis is that an agent containing DI alone could
inhibit binding of the pathogenic aPL to whole β2GPI (14). We
have developed a method of expressing recombinant human DI
in bacteria and have optimized this method to obtain high yield
and purity of DI (15). We and others previously showed that
recombinant DI inhibits binding of polyclonal IgG from patients
with APS (APS-IgG) to whole human β2GPI (8, 9). We have
also shown that recombinant DI inhibits thrombosis induced by
human APS-IgG in a murine model (16). In these experiments,
we tested wild-type DI as well as two variants created by site-
directedmutation. One variant, withmutations of aspartic acid to
serine at position 8 and glycine at position 9 (D8S,D9G) retained
the ability to block both binding and thrombogenic properties of
APS-IgG (16). We therefore decided to pursue the development
of both wild-type DI and DI (D8S,D9G) as potential therapeutic
agents for APS.
The small size (7 kDa) of DI would lead to a short half-life
in-vivo, making it unsuitable as a therapeutic agent. There are a
number of different ways to modify small biological molecules to
improve half-life. These include addition of an immunoglobulin
Fc region, as with the TNF blocking drug etanercept, and the
chemical addition of polyethylene glycol groups (PEGylation).
PEGylation has been used to develop a number of drugs
used in rheumatic diseases notably pegloticase for gout and
certolizumab pegol for rheumatoid arthritis [reviewed in (17)].
The advantages of PEGylation include improved half-life and
reduced immunogenicity but potential disadvantages include loss
of biological efficacy due to the large PEG group(s) blocking
interaction of the protein with its physiological ligand (18–21).
Larger PEG groups enhance half-life but reduce activity (19, 20,
22, 23) thus it is important first to assess activity of different
PEGylated variants of a protein before going on to select a specific
PEG size as successful development of a PEGylated therapeutic
relies on efficiently balancing these two opposing conditions.
Site-directed PEGylation on disulfide bonds enables control
of both the number and location of the PEG groups added
to a protein, so that the properties of the PEGylated product
are predictable and reproducible (24). DI has two disulfide
bonds making it suitable for this method. The ideal product is
monoPEGylated DI because two separate PEG groups attached
to the same DI molecule would probably interfere with the ability
of aPL to bind to their epitope (25–27).
In this paper we describe the PEGylation of both recombinant
wild-type DI (WT-PEG-DI) and the D8S,D9G variant [PEG-
DI (D8S,D9G)], and the characterization of their chemical and
biological properties. We include a comparison of variants
carrying PEG molecules of different sizes to facilitate future
selection of a lead product to take forward to pharmacokinetic
testing.
METHODS
A full description of the methods, including extended details
of pH, media, buffers, and mouse experiments is included in
Supplementary Material.
Expression of Recombinant DI and
DI(D8S,D9G) in Bacteria
Production was carried out as described previously (15). E. coli
BL21∗ cells were transfected with the recombinant DI plasmid
and expression of DI was achieved by adding 1mM IPTG
followed by incubation with shaking overnight at 20◦C. The
bacteria were dissolved in lysis buffer, sonicated, and centrifuged
to collect inclusion bodies containing the protein of interest.
Inclusion bodies were dissolved and ground using a pestle and
mortar into a chaotropic buffer before sonication (50% intensity,
50% cycles, 8min) to increase solubilization. The expression
plasmids are designed such that a nickel-binding hexahistidine
tag is present at the N-terminal end of expressed DI, separated
from it by a site for the protease Factor Xa (FXa) (15). The
expressed protein from the solubilized inclusion bodies was
therefore purified on a nickel column, re-folded in 0.6M arginine
buffer with a cysteine redox buffer (pH 8.5) and dialysed against
20mM Tris, 0.1M NaCl, pH 8. Protein was again purified post-
folding using a nickel column and dialysed against phosphate
buffered saline (PBS).
PEGylation
Protein was reduced at a concentration of 0.4 mg/ml in
2M arginine, 20mM sodium phosphate (NaPO4, 0.1M NaCl),
40mM EDTA at pH 8.0 with 0.1M DTT for 1 h at 20◦C. This
process was followed by removal of the reductant and buffer
exchange on a PD-10 column to an identical buffer with 25mM
arginine rather than 2M. PEGylation reagent was added (1:0.8
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molar ratio) and incubated for 4 h at 4◦C. This solution was then
buffer exchanged to 20mM sodium acetate with 0.05% Tween
at pH 6.0 for cation exchange purification on a 5ml SP-HP
column (GE Healthcare) with a linear gradient from 20% buffer
containing 1M NaCl to 100% of the same buffer at 2 ml/min for
1 h. Fractions containing protein of the expected size of PEG-
DI were identified by peaks on a chromatogram at 280 nm and
then pooled. The hexahistidine tag was cleaved using FXa as in
McDonnell et al. (15). Quantification from this point onwards
was by BCA for both PEGylated and non-PEGylated form, thus
20 µg of WT-DI contains the same amount of DI as 20 µg
WT-PEG-DI.
Quantification
All concentrations of constructs were quantified using the BCA
method. This method measures only the protein component
of the construct (i.e., DI) and is unaffected by PEG. The
concentrations expressed are based on protein concentration of
the PEGylated constructs. This method was chosen as the form
of quantification as previous work showed UV quantification
was biased by the presence of a ring group in the PEGylation
reagent. Thus, when we refer to 20µg PEG-DI, we mean 20µg of
DI within the PEG-DI construct. Therefore, the PEGylated and
non-PEGylated constructs contain the same amount of antigenic
sites.
Chemical Characterization
Proteins were characterized for purity by reverse phase high
performance liquid chromatography (RP-HPLC) using a C8
column with a linear gradient between 2% Acetonitrile (AcN),
0.05% trifluoroacetic acid (TFA), and 100% AcN 0.065% TFA.
Proteins were also characterized by SDS PAGE for size.
Production of APS-IgG Samples From
Serum of Patients
The clinical and serological data for the patients are shown in
Table 1. IgG was purified from serum of these patients by passing
these samples down a protein G column (Pierce). Eluted IgG was
neutralized with 500 µl of 1M Tris solution. Samples were then
dialysed against PBS and total IgG content was quantified using a
BCA assay.
Competitive Inhibition Anti-β2GPI ELISA
This ELISA was carried out as described previously (15). In brief,
serum was diluted 1:50 in PBS/1% bovine serum albumin (BSA)
and tested for binding in an anti-β2GPI ELISA. For each serum
sample, the dilution level giving 50% of maximum binding in
this assay was selected for use in the inhibition assay. Samples
at this dilution were incubated with varying concentrations of a
DI construct for 2 h at room temperature then tested again in
the anti-β2GPI ELISA. The results were plotted as “% Binding
remaining” on the y-axis against concentration of inhibitor on
the x-axis where “% Binding remaining” = (Binding in presence
of inhibitor)/(Binding in absence of inhibitor)× 100.
TABLE 1 | Clinical and serological data for patients with APS whose samples













Mean aCL (GPLU) 64 (SD 36)
Mean aB2GPI (GBU) 54 (SD 44)




Patient data for those used to test for activity for D8S,D9G and WT protein. Note that
cut-off for positivity in the aCL assay is >17GPLU, in the β2GPI assay it is >8GBU, and
for DI positivity it is >10 GDIU. All cut off values were derived from 200 healthy patients.
Modified Direct Russell Viper Venom Test
(dRVVT)
Although APS is characterized by increased clotting caused by
aPL, one of the tests used in clinical practice to detect aPL in
serum is called the lupus anticoagulant (LA) test. The rationale
of this test is that when clotting is triggered in-vitro using a
reagent containing dilute Russell Viper Venom, the effect of
adding aPL from a patient with APS is to inhibit clotting,
prolonging the clotting time. This effect is reversed by adding
an excess of phospholipids. The result is therefore expressed
as the ratio of dRVVT-stimulated clotting time of the patient’s
plasma in the absence of phospholipid (LA-sensitive reagent or
LS) to the clotting time in the presence of phospholipid (LA-
resistant reagent or LR). A ratio above 1.1 suggests the presence
of a circulating inhibitor of coagulation. This ratio was devised
based on healthy control data, previously published studies and
is suggested in the manufacturer kit insert.
We modified the dRVVT to test whether our PEG-
DI products inhibits prolongation of the dRVVT clotting
time caused by APS-IgG. APS-IgG samples were added to
commercially available healthy human plasma at a concentration
of 500µg/ml for 15min at 37◦C before testing in the modified
dRVVT assay. Those APS-IgG that gave LS/LR ratios >1.1 were
used for inhibition assays. APS-IgG was incubated with inhibitor
(DI or PEG-DI) at a 1:1 molar ratio with 50 µl of plasma for
15min at 37◦C. This mixture was then added to 350 µl of plasma
and re-incubated for 15min before testing for an LA-like effect.
The outcome measure was ratio of clotting times seen in the
presence of LS and LR reagents (LS/LR ratio). Reduction in
this LS/LR ratio in the presence of DI or PEG-DI signified an
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inhibitory effect on the prolongation of the modified dRVVT
caused by addition of APS-IgG. In control experiments, we used
octreotide (a kind gift from Dr. Kozakowska of PolyTherics) or
albumin (Sigma Aldrich) instead of DI or PEG-DI to exclude a
non-specific effect of adding extraneous proteins to this assay.
Passive Transfer Mouse Model
The method was as described in previous papers (16). Male
CD-1 mice (n = 5 per group) (Charles River Laboratories,
Wilmington, MA) between 6 and 8 weeks in age were injected
intraperitoneally (IP) with 500 µg in 1ml APS-IgG in (all
injections from a single preparation of IgG) and then 30–60min
later with either DI, PEG-DI conjugate or PBS control. IgG
was isolated from a Caucasian 37 year old female APS/SLE
patient with a history of pregnancy morbidity and venous
thrombosis, serum levels of aCL, aβ2GPI, and aDI were 114
GPLU, 361 GBIU, and GDIU, respectively. IgG aβ2GPI levels
were measured in the purified IgG as 132 SGU by INOVA
Quantalite ELISA assay, aDI levels previously measured were
60 GDIU (at 100µg/ml). Negative control mice were injected
IP with 500 µg in 1ml normal healthy serum (NHS)-IgG. All
materials had endotoxin levels below 1.5 EU/ml. These injections
were repeated after 48 h and the thrombogenicity of aPL was
assessed at 72 h after the first injection. At this time, mice
were anesthetized and one of the femoral veins was exposed
for observation with an approximate 0.5mm segment trans-
illuminated using a microscope equipped with a closed-circuit
video system. The isolated vein segment was pinched to introduce
a standardized injury and thrombus formation and dissolution
was visualized and recorded. The treatment groups were as
follows: APS-IgG + PBS control, NHS-IgG Alone, APS-IgG +
40 µg non-PEGylatedWT-DI, APS-IgG+ 40 µg non-PEGylated
DI (D8S,D9G), APS-IgG + 40 µg 20 kDa PEGylated DI, APS-
IgG + 40 µg 20 kDa PEGylated DI (D8S,D9G), APS-IgG +
20 µg 20 kDa PEGylated DI, PEG alone, and APS-IgG +
PEG.
Three outcome measures were assessed, as fully described in
previous papers and in Supplemental Data (16). These were:
a) Induced thrombus size: A total of three thrombi were
generated in each mouse and the largest cross-sectional area
of each thrombus during the formation-dissolution cycle was
measured five times and a mean value calculated (in µm2).
b) Activity of tissue factor (TF) in peritoneal macrophages by a
chromogenic assay. Results were standardized with reference
to the protein concentration of lysates and expressed in
pM/mg/ml.
c) Tissue Factor expression in mouse carotid homogenates
[measured as described in (b) above].
All animals were housed in the viral antibody-free barrier facility
at the University of Texas Medical Branch (UTMB). Animal use
and care were in accordance with the UTMB Institutional Animal
Care and Use Committee (IACUC) guidelines.
Statistical Analysis
Results were expressed as means plus or minus standard
deviation as appropriate. A one way analysis of variance by
ANOVA followed by the Tukey-multiple comparison test was
used to compare differences among mouse groups. These
analyses were performed using the xlStat. Statistics were also
carried out in prism using ANOVA and T-Tests. Statistical
analysis primarily compared PEGylated DI variants with their
non-modified equivalent.
RESULTS
WT-PEG-DI Was Produced at Over 95%
Purity and monoPEGylated Variants
Containing 20, 30, and 40 kDa PEG Were
Obtained
As can be seen in Figures 1A,B, 20 kDa WT-PEG-DI, 30 kDa
WT-PEG-DI, and 40 kDa WT-PEG-DI were generated and
the purity of this product exceeded 95%. Since DI contains
two disulfide bonds, the potential products of the reaction
were diPEGylated DI, monoPEGylated DI, and residual non-
PEGylated DI. The chromatogram in Figure 1C shows that
monoPEGylated DI was the dominant product and could
be easily separated in different fractions from the other two
products. The fractions shown in the chromatogram were
run on an SDS-PAGE gel (Figure 1D), which shows that
monoPEGylated, diPEGylated, and non-PEGylated DI were all
obtained separately.
WT-PEG-DI Retains the Ability to Inhibit
Binding of Serum From Patients With APS
to Whole β2GPI
Figures 2A,B demonstrate the results obtained in the inhibition
ELISA with serum samples from six patients with APS.
Binding to β2GPI on the plate was inhibited by increasing
concentrations of the following products; non-PEGylated wild-
type DI (WT-DI), WT-PEG-DI, non-PEGylated DI (D8S,D9G),
and PEG-DI (D8S,D9G). Greater inhibition is shown by lower
curves, signifying that less of the original binding capacity was
maintained in the presence of the inhibitor.
For most of the samples there is little difference between
the DI and DI(D8S,D9) curves, whether PEGylated (compare
Green with Purple), or non-PEGylated (compare Red with Blue)
showing that introduction of the D8S,D9G mutations had little
effect on inhibitory capacity of DI in this assay.
The effect of PEGylation, this can be seen by comparing the
WT-DI (Red) to WT-PEG-DI (Green) and the DI(D8S,D9G)
(Blue) to PEGylated DI(D8S,D9G) (Purple). The samples can
be divided into two types. One type, exemplified by panel
A was characterized by strong inhibition (80% or more) by
the two non-PEGylated products whereas their PEGylated
equivalents were still able to inhibit binding but not by as much
(typically a maximum of 40–50%). The other type of patient,
exemplified by panel B showed less inhibition of binding but
this level of inhibition (typically a maximum of 30–50%) was
similar for the non-PEGylated and PEGylated DI molecules. Of
note, in direct anti-DI ELISA the type A samples had higher
binding to DI (mean 87.5GDIU) than the type B samples
(mean 44.4GDIU).
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FIGURE 1 | Production of monoPEGylated DI. (A) A chromatogram demonstrating the production of >95% pure conjugated WT-PEG-DI shown as a single peak by
Reverse Phase HPLC using a C18 column. (B) SDS PAGE gel showing unmodified WT-DI (lane 1), WT-DI conjugated to 20 kDa PEG (lane 2), WT-DI conjugated to 30
kDa PEG (lane 3), and WT-DI conjugated to 40 kDa PEG (lane 4). The red box around lane 2 indicates the sample shown in chromatogram (A). (C) Chromatogram
showing the result of cation exchange purification to separate non-conjugated WT-DI from PEG-WT-DI. The peak at 225ml is diPEGylated WT-DI. The large peak at
260ml, highlighted by the red box, is monoPEGylated WT-DI. The small peak at 320ml is residual non-PEGylated WT-DI. (D) SDS PAGE gel showing the different
forms of WT-PEG-DI obtained from the cation exchange purification (C). The Bands in the three lanes at the far left are diPEGylated WT-DI. Bands in the center,
highlighted by the red box, are monoPEGylated WT-DI. The faint bands in the lanes on the far right are residual non-PEGylated WT-DI.
We then compiled all the patient data into a single graph
displaying average inhibition within groups (Figure 2C). We
utilized the 100 mcg dose as this concentration was before the
plateau of inhibition; these data are shown in Figure 2C. It
demonstrates that 20 kDa WT-PEG-DI (n = 10), 30 kDa WT-
PEG-DI (n = 6), and 40-kDa WT-PEG-DI (n = 9) all inhibit
binding to a similar level. When combining the results from
testing multiple serum samples, there was no significant loss of
inhibitory capacity with the PEGylated compared to the non-
PEGylated variants.
PEGylated DI Retains the Ability to Inhibit
the Effect of APS-IgG in the Modified
dRVVT Assay
The outcome measure in this assay is the ratio of clotting time in
the presence of the lupus anticoagulant-sensitive (LS) reagent to
clotting time in the presence of the lupus anticoagulant-resistant
(LR) reagent—referred to in the figure as LS:LR ratio or ratio of
reagents. As described in the methods section, a reduction in this
ratio in the presence of DI or PEG-DI indicates inhibition of the
prolongation of the dRVVT.
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FIGURE 2 | PEGylated DI blocks binding of IgG in APS serum samples to whole β2GPI. (A) This graph shows the combined results from inhibition ELISAs of serum
samples from three patients whose binding to whole β2GPI was inhibited more strongly by non-PEGylated than by PEGylated DI constructs. (A) Contains patients
with a high level of serum aDI antibodies (average >80 GDIU). (B) This graph shows the combined results from inhibition ELISAs of serum samples from three patients
whose binding to whole β2GPI was inhibited equally by non-PEGylated and PEGylated DI constructs. These patients have a lower level of serum aDI (average <45
GDIU). (C) The dot bot shows the combined results from testing samples from 9 patients [including all six from (A,B)]. The first column on the left shows binding to
β2GPI in the absence of any inhibitor and the other columns show the binding in the presence of different inhibitors at a concentration of 100µg/ml. For both WT-DI
and DI(D8S,D9G), addition of 20 kDa PEG does not alter the inhibitory capacity of DI in this assay and the same is true for 30 and 40 kDa PEG in the case of WT-DI
(these larger PEG sizes were not tested for DI(D8S,D9G). Significant differences were seen between the results obtained with APS IgG alone and those obtained with
all inhibitors PEGylated or non-PEGylated (***p < 0.005, **p < 0.05) but no significant differences were seen between any of the inhibitors.
Results from 9 samples can be seen in Figure 3A. There was
significant inhibition (P< 0.05) with non-PEGylatedWT-DI and
both 20 kDa WT-PEG-DI and 40 kDa WT-PEG-DI. PEGylation
did not reduce the ability of WT-DI to inhibit the action of
APS-IgG in this assay. Furthermore, Figure 3B shows the results
for each sample separately. For two samples, the PEGylated
variants reduced LS:LR ratio more than non-PEG-DI. WT-PEG-
DI showed no effect on the clotting of normal plasma in the
absence of APS-IgG. PEG alone showed no inhibitory effects
(data not shown).
Figure 3C shows the results of control experiments designed
to show that only proteins containing DI inhibited APS-IgG in
this assay. We added octreotide or two different preparations of
albumin to either APS-IgG or control IgG preparations [from
a patient with systemic lupus erythematosus (SLE) or a healthy
subject]. The figure shows that neither albumin nor octreotide
had any effect on the LS:LR ratio obtained with any of these
samples.
Figure 3D shows the results of samples from three patients
for which inhibitory effects of both WT-DI and DI(D8S,D9G)
were tested. Both PEGylated and non-PEGylated forms of both
these agents inhibited the LA-like effect of APS-IgG in these
experiments.
PEGylated DI Retains the Ability to Inhibit
the Effect of APS-IgG on Development of
Thrombosis in a Mouse Model of APS
In each panel of Figure 4, the two columns on the far left
show the difference in outcome obtained after administering
APS-IgG and NHS-IgG in the absence of any inhibitor. In
Figure 4A the following two columns show that PEG alone does
not cause enhanced thrombosis (compared to NHS-IgG) nor
does it inhibit the thrombotic effect of APS-IgG. The next two
columns compare the WT-DI and DI(D8S,D9G) non-PEGylated
proteins for their ability to inhibit thrombosis; both significantly
reduce thrombus size. The following two columns show that
20 KDa WT-PEG-DI also inhibits thrombosis, but not as well
as non-PEGylated WT-DI, with little difference between the 20
and 40 µg doses. However, the two columns on the far right
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FIGURE 3 | PEGylated DI inhibits the LA effect of APS-IgG samples. In each figure, the y-axis shows the ratio of clotting times obtained in the presence of LS and LR
reagents. LS:LR value >1.1 suggests an LA effect. (A) Demonstration of the effect of inhibitors on a modified dRVVT assay, this graph shows combined results from
testing 9 samples. The mean LS:LR ratio was significantly lower in the presence of non-PEG-DI, 20 or 40 kDa WT-PEG-DI than in the absence of any of these agents.
Significance was seen with all inhibitors compared to no inhibition (*p < 0.05) but there were no significant differences between the results obtained with non-PEG-DI,
20 and 40-kDa-PEG-DI. (B) Each separate line shows results from IgG of an individual patient inhibited with PEGylated and non-PEGylated Domain I in the modified
dRVVT assay. The LS:LR ratios obtained with PEG-DI are either similar to or lower than those obtained with non-PEG-DI for all samples. (C) Control experiment
showing that addition of non-DI proteins (albumin and octreotide) has no effect on LS:LR ratios in this coagulation assay. Each group of five columns shows the results
from blood of a single individual (two with APS, one with SLE but not APS, and one HC) and in each group there are no significant differences between the columns.
(D) Comparison of WT-DI and DI(D8S,D9G) in tests on three samples. Here PEG-DI(D8S,D9G) and non-PEG-DI(D8S,D9G) have similar effects to each other but less
than WT-PEG-DI.
show a marked loss of inhibitory activity of DI(D8S,D9G) after
PEGylation, especially at the 20 µg dose.
Figure 4B shows TF expression in peritoneal macrophages of
mice exposed to APS-IgG in the presence of various inhibitors.
The columns on the left (3–5) show inhibition by both PEGylated
and non-PEGylatedWT-DI whereas the columns on the right (8–
10) show that the inhibitory effect of DI(D8S,D9G) in this assay
is dramatically reduced after PEGylation. In fact, Figures 4A,B
show that a dose of 20 µg PEG-DI(D8S,D9G) has no inhibitory
effect at all. PEG in the absence of APS-IgG does not have any
effect on TF expression in peritoneal macrophages.
As can be seen in Figure 4C both non-PEGylated WT-
DI and WT-PEG-DI inhibit the expression of TF in mouse
carotid exposed to APS-IgG by similar amounts. Conversely DI
(D8S,D9G) does not significantly reduce carotid TF expression,
whether or not it is PEGylated.
Since the mice in this model are subjected to anesthesia and
a surgical procedure, some premature deaths were expected. All
but one of these deaths occurred while mice were still under
anesthesia. Thus, in the control groups that were not exposed
to DI, 1/5 mice died in each of the following groups; APS-IgG
alone, NHS IgG alone, and PEG alone and no mice died in
the group of 7 mice given APS IgG and PEG. The results were
similar in the mice given APS-IgG plus non-PEGylated WT-DI
(1/5 died) and APS-IgG plus non-PEGylated DI (D8S,D9G) (0/5
died). Regarding the PEGylated constructs, two different doses
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FIGURE 4 | Inhibitory effects of non-PEG-DI and PEG-DI in a passive transfer mouse model of APS. Mice received either NHS-IgG (500 µg), APS-IgG (500 µg), or 40
µg PEG alone with no IgG. APS-IgG, but not NHS-IgG or PEG alone, stimulated increased thrombosis (A), increased peritoneal macrophage TF expression (B), and
increased carotid TF expression (C). The effects of the various PEGylated and non-PEGylated DI constructs are shown in the columns on the right of the graphs and
explained fully in the results section.
of PEG-DI were tested. At high dose (40 µg) 2/5 mice died in
both the APS-IgG plus PEG-WT-DI and the APS-IgG plus PEG-
DI(D8S/D9G) group. However, at low dose (20µg) 0/5 mice died
in the APS-IgG plus PEG-WT-DI and 2/5 died in the APS-IgG
plus PEG-DI(D8S/D9G) group.
We carried out analyses to investigate possible causes of
toxicity in these mice. Mice treated with high dose of PEG-
WT-DI and either dose of PEG-DI(D8S/D9G) displayed some
signs of inflammatory damage localized to the peritoneal cavity
manifesting as erythema, exudation, and in the case of some
of the animals treated with the PEG-DI(D8S,D9G) agent,
petechial hemorrhage. However, none of the mice exhibited
any of the typical signs of a systemic inflammatory response,
namely coat ruﬄing, impaired consciousness, activity, eye
movements, respiration, or response to stimuli. Importantly,
the mice exposed to low dose PEG-WT-DI had neither
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localized nor systemic inflammation and none of them died
prematurely.
We measured the levels of the acute phase reactants
interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) inmice
treated with the 40 µg dose of PEG-DI(D8S,D9G) or PEG-WT-
DI and found that they were similar to those seen in mice treated
with a low dose of endotoxin (0.001mg), which does not cause
systemic inflammation. These levels were∼10 to 60-fold less than
those seen inmice treated with a typical endotoxin dose to induce
sepsis (0.5mg).
In summary, these mortality data showed that administration
of the non-PEG-DI and low dose PEG-20kDaWT-DI did not
demonstrate any excess deaths compared to control groups,
whereas the PEG-20kDa DI(D8S/D9G) group had a slight excess
(2/5 deaths compared to 1/5 in control groups) at either dose.
Thus, the PEGylated mutant version of DI showed unfavorable
properties in this in-vivo model compared to PEGylated WT-DI
both in terms of activity (see above) and toxicity.
DISCUSSION
We previously showed that recombinant DI expressed in bacteria
blocked the binding and thrombogenic actions of APS-IgG (16).
Since DI alone is not a viable therapeutic agent due to its
small size, we have pursued development of a PEGylated form
of DI. The use of PEGylation is common in the production
of therapeutics due to its positive pharmacokinetic effects,
however, this is weighed against a loss of activity for the
protein. For this reason it is essential to characterize protein
activity to determine which size of PEG would be optimal in
terms of balancing increased half-life with maximal activity,
prior to testing pharmacokinetics. Equally, before proceeding
to trials of efficacy, it was important to optimize the method
of production of pure monoPEGylated DI. The optimization
of expression of DI in E. coli has been reported in a previous
paper (15) and the optimization of PEGylation and purification is
reported here.
Total inhibition of binding of APS-IgG to β2GPI was not
seen even at high concentrations of PEG-DI because the serum
anti-β2GPI response in patients with APS is polyclonal and
comprises antibodies to different domains of β2GPI. The anti-
DI component of this polyclonal response is believed to play
the predominant role in pathogenesis of the APS. Both a Dutch
group de Laat et al. (28) and our group have shown that anti-DI
levels are more closely associated with risk of thrombosis than
anti-β2GPI or anti-cardiolipin antibody levels (29). Andreoli
et al. tested serum from a variety of groups for antibodies to
DI and to DIV/V (30). Whereas anti-DI and anti-DIV/V were
equally likely to be found in subjects with no autoimmune
disease, anti-DI was found four times more commonly than
anti-DIV/V in autoimmune patients (30). In a mouse model,
we showed that when APS-IgG was separated into anti-DI-
rich and anti-DI-poor fractions by affinity-purification on a
column carrying recombinant DI, the ability to cause vascular
thrombosis was concentrated in the anti-DI rich fraction (31).
Thus, we believe that 50% inhibition of binding of APS-IgG to
β2GPI that we have demonstrated with PEG-DI is of potential
clinical benefit, because the subpopulation of anti-β2GPI being
inhibited is also the group with the major thrombogenic
effect.
Our description of a modified dRVVT assay to test the
ability of potential therapeutic agents to block the ability of
APS-IgG to prolong the modified dRVVT is itself novel and
could be used to test other potential therapeutic agents in
APS, however, further testing is required before the modified
dRVVT could be considered a reliable marker. Testing the
LA-like effect is relevant as several studies have shown that
LA may be a stronger predictor of clinical outcomes than the
anti-cardiolipin or anti-β2GPI tests in patients with SLE and
APS (32), particularly in pregnancy (33). WT-PEG-DI was at
least as effective an inhibitor in this assay as non-PEG WT-DI.
However, unlike the binding assay [where we obtained similar
results with WT-DI and DI (D8S,D9G)] in the modified dRVVT
assay PEGylation seems to reduce the efficacy of DI (D8S,D9G).
Replacing two larger negatively charged amino acids with smaller
neutral ones could alter exposure of the disulfide bond to which
the PEG binds and might therefore alter the orientation of
the PEG group itself, thus influencing factors such as steric
hindrance.
In the mouse model experiments, it was also clear that WT–
PEG-DI had advantages over PEG-DI (D8S,D9G). Whereas,
both 20 µg WT-PEG-DI and 40 µg WT-PEG-DI inhibited the
biological effects of APS-IgG on thrombosis and TF expression,
the PEGylated forms of DI(D8S,D9G) had reduced efficacy as
inhibitors. Furthermore, significant toxicity was seen with the
PEG-DI(D8S,D9G) agent but not the WT-PEG-DI agent. While
the 20 and 40µg doses of the PEG-DI(D8S,D9G) agent produced
inflammatory damage, resulting in premature deaths of 40% of
the mice in each group, the WT-PEG-DI agent did not have this
effect when given at a dose of 20µg.
It was not possible to use the mouse model to establish half-
lives of the DI or DI-PEG conjugates for several reasons. In this
acute model, mice are sacrificed after 72 h, as such little data
would be generated regarding the half-lives of protein from such
a small exposure. Equally, DI or PEG-DI is bound by circulating
antibody, this would alter the values detected if we attempted to
use this model to characterize half-lives. The aim of the mouse
model was to characterize the activity of the conjugates before
establishing a lead candidate for therapeutic development, it is
only through initially testing the activity of the protein conjugates
that the correct PEG size can be tailored to the protein.
Although the ultimate purpose in PEGylating DI was to
improve its serum half-life, we have not yet carried out
pharmacokinetic experiments to prove that this has been
achieved. Clearly these experiments must be done before clinical
application of PEG-DI can be considered, furthermore, we also
plan to test ability of PEG-DI to inhibit thrombus formation in a
chronic mouse model of APS, in which mice are immunized with
human β2GPI and thus develop their own anti-β2GPI antibodies
(34) (as opposed to the passive transfer of human APS-IgG
reported in this paper).
We are unsure of the exact mechanism of toxicity attributed
to the PEGylated DI(D8S,D9G) but it seems clear that it is
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localized to the site of inoculation and given the changes in size
and charge to the DI molecule imparted by the PEG conjugate,
impaired absorption of the agent across the peritoneum may be
a contributing factor. Importantly, we ruled out the formation of
immune complexes (CIC) in the peritoneal cavity as a possible
cause by measuring levels in collected peritoneal exudates (data
not shown). Future toxicity studies will focus on determining
specific effects of PEGylated agents when introduced in the
intraperitoneal vs. intravascular compartments.
We hypothesize that the difference in activity in-vitro and
toxicity in-vivo between the two conjugates may be due to
a difference in the binding site of the PEG. The PEGylation
technology used requires access to surface exposed disulphide
bonds. The dual mutation in the DI(D8S,D9G) protein allows
access to the disulphide from two sides whilst the WT-DI protein
restricts access to a single site. The mutations may therefore
allow a different PEGylation which in turn may lead to masking
the active site. This difference in site could also explain the
increased toxicity seen with the PEG-DI(D8S,D9G) agent as the
difference in PEGylation site may also effect diffusion constants
and solubility. This theory is, however, speculative and would
require significant modeling work to fully confirm.
Overall, the results of our programme of experiments
clearly identify WT-PEG-DI as a strong potential lead for APS
and a better candidate than PEG-DI(D8S,D9G), though the
optimal size of PEG cannot be identified until pharmacokinetic
experiments have been carried out.
Limitations of the work include the fact that we have tested
samples from a relatively small number of patients with APS.
Particularly for the in-vivo experiments there are practical
limitations to the number of different samples that can be tested,
since large numbers of mice are required for tests on each APS-
IgG sample. For the modified dRVVT assay we can only use
samples that have LS:LR >1.1 in the absence of inhibitor. We
have mitigated the problem of limited sample numbers by using
three complementary assays to test efficacy of PEG-DI as an
inhibitor of APS-IgG. We should stress however, PEG-DI may
not be effective in all patients; potentially it may show greatest
effect in patients with high anti-DI levels. Measuring anti-DI
levels could identify the sub-population of patients with APS
likely to respond to PEG-DI. A study by Pericleous et al. showed
∼40% of patients with APS had aDI positivity (29), a finding
mirrored by a recent review (35).
Possible limitations of PEG-DI include potential toxicity
or immunogenicity of the PEG molecule. PEG is harmless
to animals at concentrations as high as 16 g per kg [1,000-
fold higher than the normal therapeutic dose of protein-PEG
conjugates in humans (26)] but anti-PEG antibodies are found
in between 8 and 25% of the healthy population (36, 37).
This phenomenon is possibly due to use of PEG in everyday
products such as hand creams. It is not clear whether those
anti-PEG antibodies would affect efficacy of PEGylated drugs.
Although anti-PEG and anti-drug antibodies adversely affected
efficacy of PEGylated uricase used in gout, the same was not
true in large clinical trials of certolizumab pegol, a PEGylated
anti-tumor necrosis factor Fab used in rheumatoid arthritis.
Though antibodies to this drug were seen in 5–6% of patients
in the RAPID 1 (38) and RAPID 2 (39) clinical trials, there was
no evidence that presence of these antibodies affected clinical
outcomes.
In conclusion, there is a pressing need for targeted therapies
in APS given that none have yet been developed for this disease.
We have developed PEG-DI, an agent designed to block binding
of pathogenic aPL to β2GPI, and have shown that it is effective
at blocking the effects of APS-IgG in three different assays, two
in-vitro and one in-vivo. These data support pharmacokinetic
and toxicology experiments which are now underway to develop
PEG-DI as a first-in-class therapeutic for APS.
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